Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company's Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30th Annual Congress
Study findings noted elevated IL-1Ra expression in synovial fluid and an encouraging trend in symptomatic improvement.
- Study findings noted elevated IL-1Ra expression in synovial fluid and an encouraging trend in symptomatic improvement.
- These data will be delivered in a poster presentation at the European American Society of Gene & Cell Therapy's (ESGCT) 30th Annual Congress being held October 24-27, 2023, in Brussels, Belgium.
- Clinical trial participants developed various degrees of anti-AAV neutralizing antibodies after injection of GNSC-001, but no capsid targeted T-cell response was detected.
- The study was supported by funding from the U.S. Department of Defense Peer Reviewed Medical Research Program (PRMRP).